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Abstract
Local injections of botulinum toxins have been reported to be useful not only for the treatment of peripheral neuropathic pain and
migraine but also to cause long-lasting muscle paralysis, a potentially serious side effect. Recently, a botulinum A-based molecule
(“BiTox”) has been synthesized that retains neuronal silencing capacity without triggering muscle paralysis. In this study, we
examined whether BiTox delivered peripherally was able to reduce or prevent the increased nociceptive sensitivity found in animal
models of inflammatory, surgical, and neuropathic pain. Plasma extravasation and edema were also measured as well as
keratinocyte proliferation. No motor deficits were seen and acute thermal and mechanical nociceptive thresholds were unimpaired
by BiTox injections. We found reduced plasma extravasation and inflammatory edema as well as lower levels of keratinocyte
proliferation in cutaneous tissue after local BiTox injection. However, we found no evidence that BiTox was transported to the dorsal
root ganglia or dorsal horn and no deficits in formalin-elicited behaviors or capsaicin or formalin-induced c-Fos expression within the
dorsal horn. In contrast, Bitox treatment strongly reduced A-nociceptor-mediated secondary mechanical hyperalgesia associated
with either complete Freund’s adjuvant (CFA)-induced joint inflammation or capsaicin injection and the hypersensitivity associated
with spared nerve injury. These results imply that although local release of neuromodulators from C-fibers was inhibited by BiTox
injection, C-nociceptive signaling function was not impaired. Taken together with recent clinical data the results suggest that BiTox
should be considered for treatment of pain conditions in which A-nociceptors are thought to play a significant role.
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1. Introduction
Botulinumneurotoxins (BoNTs), ofwhich there are 7 serotypes, are
the most lethal toxins known to man.10,30,31,42 Botulinum
neurotoxin/A (Botox), the serotype most commonly used in clinical
practice, acts on synaptic transmission by cleavage of the specific
target SNAP-25, a member of the SNARE (Soluble
N-ethylmaleimide-sensitive factor attachment protein receptor)
family of proteins, preventing the correct assembly of the SNARE
core complex and thus the fusion of synaptic vesicles with the
neuronal presynaptic membrane, inhibiting the release of neuro-
transmitter.3,44 This occurs both peripherally and within the central
nervous system after local injection of the toxin, reversibly silencing
synaptic transmission.12,32 Peripheral injections of BoNT/A inhibit
exocytosis of acetylcholine from motor nerve terminals causing
flaccid muscle paralysis, a property that has made BoNT/A useful
for the treatment of many pathological conditions, involving
excessive muscle contractions. However, although the specificity
of BoNT/A for motor neuron terminals is established, an
antinociceptive role of the toxin by binding to nociceptive primary
afferents has also been suggested and indeed BoNT/A injections
for chronic pain have become a valuable tool in clinical practice.
Recent meta-analyses of the clinical literature have recommended
local BoNT/A treatment for peripheral neuropathic pain.11 Botu-
linum neurotoxin/A has also shown effectiveness in the treatment
for chronic migraine after injections in the scalp muscles.14,25
There is, however, considerable confusion over the mecha-
nism of BoNT/A-mediated antinociception. For example, a recent
study using healthy volunteers reported that intradermal admin-
istration of BoNT/A inhibited local protein extravasation and
produced a marked decrease in noxious mechanical pain
sensitivity although sensitivity to thermal stimuli was un-
changed.35 C-nociceptors have been implicated as targets of
BoNT/A, as they release neuropeptides substance P (SP) and
calcitonin gene-relatedpeptide peripherally after local inflammation
causing local vasodilatation and plasma extravasation.16–18,35
Plasma extravasation can be blocked in humans and rodents by
local injections of BoNT/A. However, the evidence that BoNT/A
also inhibits C-fiber nociceptive function is far less clear and in both
clinical and preclinical studies the main effect of BoNT/A seems
to be on relieving neuropathic rather than inflammatory
pain.2,15,27,39,47,49,50
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Recently, a nonparalytic and therefore safer version of the
botulinum molecule (BiTox) has been synthesized by “stapling”
together the recombinant light chain/translocation domain and
receptor-binding domain of BoNT/A. This chimeric molecule
exhibited the same “silencing” efficacy on neurons as the native
BoNT/A but had significantly reduced paralytic activity a dose-
limiting serious side effect of repeated BoNT/A treatment.6,12,13 In
this study, we examine the potential antinociceptive effect of BiTox
on acute and chronic inflammatory pain as well as in surgical and
neuropathic pain models, evaluating the potential of BiTox to
replaceBoNT/A as a safe treatment for some types of chronic pain.
2. Methods
2.1. Animals
All procedures complied with the UK Animals (Scientific
Procedures) Act 1986. Male Sprague Dawley rats (weighing
170-200 g; Central Biological Services, University College
London, United Kingdom) were used. Animals were kept in their
home cages at 21˚C and 55% relative humidity with a light to dark
cycle of 12 hours (lights on at 08:00 hours). Food and water were
provided ad libitum. All efforts were made to minimize animal
suffering and to reduce the number of animals used. A total of 150
animals were used for the study.
2.2. Preparation of BiTox
BoNT/A consists of 3 structurally independent units: the
Receptor-binding domain (Rbd), the Translocation domain
(Td), and the Light chain (Lc), the last being the “silencing
domain” a proteolytic enzyme. Here we use a process called
SNARE tagging to bind recombinant proteins together. Thus
the light chain translocation domain part of the BoNT/A
molecule is linked with SNAP25 and the receptor-binding
domain component is linked with synaptobrevin. These
recombinant proteins were expressed in bacteria and then
mixed with syntaxin protein. Syntaxin, SNAP25, and synapto-
brevin bind together to form stable tetrahelical synthetic
molecules (see Fig. 2, Ref. 11). Previously, it was shown that
the assembled BiTox molecule had unique nonparalyzing
properties compared with BoNT/A.11
Briefly, all proteins were expressed in BL21 strain of E. coli as
glutathione S-transferase C-terminal fusions cleavable by thrombin.
Proteins fused to glutathione S-transferase were purified on
Glutathione Sepharose beads (GE Healthcare, Buckinghamshire,
United Kingdom) and eluted from beads in 20 mM Hepes, pH 7.3,
100 mM NaCl (Buffer A) using thrombin. Further purification was
achieved by gel filtration using a Superdex 200 10/200GLcolumn
(GE Healthcare). The BiTox was assembled by mixing the SNARE-
tagged proteins with syntaxin peptide (Peptide Synthetics, Hamp-
shire, United Kingdom) for 30minutes at 20˚C, each component at 5
mMconcentration. To visualizeSNAREassemblies, SDS-PAGEwas
performed at 4˚C, and the gels were stained with Coomassie blue.
Cleaved SNAP25 was derived from SIMA neuroblastoma cells
treated with BiTox for 3 days as previously described.6,12 BiTox
was generally used at a dose of 200 ng in 50 mL saline unless
otherwise stated.
2.3. Drugs delivery and surgery
2.3.1. Intraplantar and intra-ankle joint injections
Under 2% isoflurane anesthesia, a 30 G needle was inserted
into the plantar surface of the paw subcutaneously. Fifty
microlitres of BiTox (200 ng in 0.9% NaCl solution) or vehicle or
50 mL of CFA (Complete Freund’s adjuvant, SIGMA,
Gillingham, United Kingdom) were injected for more than 10
to 20 seconds. Fifty microlitres of 2% formalin or 10 mL of 0.3%
capsaicin N-vanillylnonanamide (synthetic capsaicin; SIGMA)
were injected without anesthesia. For the latter, the animal was
lightly restrained in a glove during injection. Ten microlitres CFA
was injected into the lateral ankle joint. For dose–response
experiments, the concentrations of BiTox used were: 2, 50,
100, and 200 ng. All BiTox injections were given in center of the
plantar surface unless otherwise stated.19,26
2.3.2. Spared nerve injury surgery
The spared nerve injury (SNI) was performed as previously
described.8 Under 2% isoflurane anesthesia, incision was made
on the skin of the thigh and through the biceps femoris muscle
exposing the 3 terminal branches of sciatic nerve: the sural,
common peroneal, and tibial nerves. The common peroneal and
tibial nerves were tightly ligated with 5.0 silk and sectioned distal
to the ligation, removing 2 to 4 mm of the distal nerve stump.
Muscle and skin were closed in 2 separate layers. Behavioral
testing began the day after surgery and continued for 11 days
postsurgery.
2.3.3. Plantar Incisional injury
All rats were anesthetized with 2% isoflurane. As described
before,4 a 1-cm longitudinal incision wasmade, with a number 11
scalpel blade, through skin and fascia of the plantar paw, starting
0.5 cm from the proximal edge of heel and extending toward the
toes. The plantar muscle was elevated and incised longitudinally.
The skin was closed with 5.0 silk sutures.
2.4. Behavioral testing
In all experiments each animal was assigned to one behavioral
test only—that is, each animal was never tested in more than one
modality, apart from the SNI groups where von Frey testing was
followed by the acetone test. The contralateral paw was also
tested but no changes in mechanical or thermal thresholds were
detected.
2.4.1. Von Frey test
Mechanical sensitivity was assessed using the von Frey filaments
(Stoelting, Wood Dale, IL). A series of calibrated von Frey
filaments exerting pressure stimuli in the range of 0.04 to 26.0 g
were used on the plantar surface of the paw in an ascending
order, starting with filament 0.04 g. Before each testing session,
animals were placed in individual plastic cages and left to adapt to
the environment for at least 20 minutes. The filaments were
applied 10 times every 5 seconds and the number of positive
responses recorded.19
2.4.2. Pinprick test
The pinprick test was performed as previously described.19
Animals were placed on an elevatedwire grid and habituated over
a period of 2 to 3 consecutive days by recording a series of
baseline measurements. The point of a safety pin was applied to
the lateral part of the plantar surface of the paw at intensity
sufficient to indent but not to penetrate the skin. The duration of
paw withdrawal was recorded with a minimum arbitrary value of
0.5 seconds for a brief response.
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2.4.3. Thermal stimulation
Thermal withdrawal thresholds were determined as previously
described.19 Animals were allowed to habituate to the apparatus
(Ugo Basile, Varese, Italy) for 10 to 15 minutes before testing
began. Rats were placed in a clear plastic chamber (18 3 29 3
12.5 cm) with a glass floor and allowed to acclimate to their
environment for 5 minutes before testing. During this time, rats
initially demonstrated exploratory behavior but subsequently
stopped exploring and stood quietly with occasional bouts of
grooming. After the acclimation the radiant heat source was
positioned under the glass floor directly beneath the hindpaw. A
trial commenced when a switch activated the radiant heat source
and started an electronic timer. This assay measured the latency
in seconds to withdrawal of the hindpaw. The heat intensity was
calibrated so that a naive, untreated animal had an average
latency of 8 to 10 seconds; to prevent tissue injury, a maximum
cut-off value was set at 20 seconds. For each animal, the
withdrawal latency was the average of 3 separate determinations,
taken with at least 2 minutes between each trial.
2.4.4. Formalin test
The rats were placed into a plexiglas observation chamber (103
20 3 24 cm) with a mirror (45˚ angle) positioned to permit
unhindered observation of the rat hindpaws. Formalin was
injected subcutaneously into the center of the plantar surface of
the left hindpaw. The rat was then replaced in the box, the clock
was started and the response was recorded for a period of 1
hour.46 The pain-related behavior was quantified by counting the
total number of flinches and shakes, rapid and brief withdrawal
movements or flexion of the injected paw, occurring for 1-minute
periods from 1 to 5 minutes (Phase I) and, then for 1-min periods
at 5-minute intervals during the period from 10 to 60 minutes
(Phase II) after formalin injection. Phase I is generally considered
the result of chemical activation of nociceptors, whereas Phase II
reflects the inflammatory reaction and central processing.46
2.4.5. Acetone test
For assessment of cold sensitivity, the acetone test was used
as described previously.8 Approximately, 30 minutes after the
von Frey test, mice were tested for pawwithdrawal response to
a cold stimulus comprising a 50-mL drop of acetone applied
to the center of the plantar surface of the hindpaw ipsilateral to
the site of injury, avoiding mechanical stimulation of the paw
with the syringe. Total time lifting/clutching ipsilateral hindpaw
was recorded with an arbitrary maximum cut-off time of 20
seconds. Before testing, animals were habituated over a period
of 2 to 3 consecutive days by recording a series of baseline
measurements.
2.4.6. Motor function
Motor function was evaluated using the hindpaw digit spreading
that occurs when the animal is picked up by the tail or by
suspension test in which animals were placed on awiremesh and
the mesh inverted. Time to fall from the mesh or weakness in the
hind limb, was noted.
2.5. Plasma extravasation measured with Evans Blue
Under 2% isoflurane anaesthesia, rats were pretreated (3 days)
with a single intraplantar (IPLT) injection of BiTox into the
hindpaw or vehicle into the plantar surface of contralateral
paw. In control groups, the vehicle was delivered into the
ipsilateral and contralateral paws. After 3 days, the animals
were deeply anesthetized once again with isoflurane and
received a tail vein injection of Evans blue (50 mg·kg21; Sigma-
Aldrich). After 15 minutes the animals received 0.3% capsaicin
into the ipsilateral (BiTox pre-injected) and 0.3% capsaicin into
the saline pre-injected contralateral paw. Rats were sacrificed
with CO2 15minutes later and the ipsi-and contralateral plantar
paws were photographed and removed. The dye was
extracted with formamide (2 mL per each plantar paw;
Sigma-Aldrich) for 72 hours at 37˚C. After the incubation, the
solvent was submitted for a spectrophotometric analysis of the
stain density (620 nm) and calibrated with a standard curve to
determine the amount of dye extravasation. Dye concentra-
tions in the ipsilateral and contralateral paws were then
compared. The area of blue staining was also measured from
photographs of each paw before extraction using an NIH
Image J imaging package.
2.6. Bromodeoxyuridine incorporation
Bromodeoxyuridine (BrdU)-labeling was used to measure
kerantinocyte proliferation in the basal epidermis. Three
different groups of animals were injected with BiTox 32 days,
14 or 3 days before BrdU injection (100 mg·kg21 in saline, i.p.;
SIGMA). The animals were killed 24 hours after BrdU injection
by deep barbiturate anaesthesia followed by transcardiac
perfusion. The skin tissues were postfixed for 2 hours in 4%
paraformaldehyde (PFA), sectioned, and subjected to immu-
nohistochemistry with BrdU antibody (see 2.7 Immunohisto-
chemistry paragraph) after pretreatment with hydrochloric acid
2N for 30 minutes to denature DNA and 0.1 M boric acid for 10
minutes to neutralize the acid. All tissue sections were
counterstained with 0.1% DAPI to reveal keratinocytes in the
basal layer of the epidermis.22,23
2.7. Immunohistochemistry
Rats were deeply anaesthetized with pentobarbital and
perfused transcardially, briefly with saline containing 5000
I.U·mL21 heparin followed by 4% PFA in 0.1 M phosphate
buffer (PB). The glabrous skin of the hindpaw and the spinal
cord were dissected out, postfixed in the same PFA solution for
2 hours and transferred into a 30 % sucrose solution in
phosphate buffer containing 0.01% azide, for a minimum of 24
hours. Tissues were cut on a freezing microtome at 40 mm. All
primary antibodies were used with a tyramide signal amplifi-
cation and immunofluorescence (as previously detailed26),
except for c-Fos when a protocol using diaminobenzidine was
used as the final step. Sections were left to incubate with the
following primary antibodies: anti-BrdU (1:200; Becton
Dickinson, Oxford, United Kingdom; Cat, No.: 347,580), anti-
cSNAP25 antibody recognizing the cleaved end of SNAP25
(TRIDEANQ) 1:10,000, and anti-c-Fos (1:10,000; Millipore,
Cat, No.: ABE457) for 24 h at room temperature. Appropriate
biotinylated secondary antibodies were used at a concentra-
tion of 1:400 for 90minutes. Samples were then incubated with
avidin biotin complex (ABC Elite; Vector Lab., CA) (1:250
Vectastain A11:250 Vectastain B) for 30 minutes followed by
a signal amplification step with biotinylated tyramide solution
(1:75 for 7 minutes; Perkin Elmer, MA). Finally, sections were
incubated with FITC-avidin for 2 hours (1:600). All sections
were coverslipped with Gel Mount Aqueous Mounting Medium
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(Sigma) to protect the fluorescence from fading and stored in
dark boxes at 4˚C. For c-Fos, immunohistochemistry sections
were incubated in anti-c-Fos antibody for 24 hours RT followed
by incubation with the biotinylated secondary antibody (1:500)
for 2 hours. Samples were then incubated with avidin biotin
complex (ABC Elite; Vector Lab.) (1:250 Vectastain A11:250
Vectastain B) for 1 hours followed by a staining step for 4
minutes in a solution containing 3,39 diaminobenzidine (DAB
Kit; Vector). All sections were left to dry overnight. Finally, the
slides were dehydrated and coverslipped with DPX mountant
(containing Xylene and DibutylPhtalate). Slides were stored at
room temperature.
2.8. Cell counts
To count the number of c-Fos-labeled neurons after formalin or
capsaicin stimulation, the superficial dorsal horn was divided into
3 ipsilateral domains: the superficial laminae I–II, laminae III–IV,
and the deep laminae V–VII. For each rat, Fos-immunoreactive
neurons in all sections were counted (the minimum distance
between sections was 200 mm), counts from the 5 most heavily
labeled sections were averaged and the mean was used for
further statistical analysis. BrdU labelled cells were counted from
photomicrographs or directly from the microscope using a 103
objective lens on a Leica DMRmicroscope and Volocity software
(PerkinElmer, Waltham, MA). Ten areas of epidermis were
counted per animal over an area of 1 mm2. Sections were at
least 200 mm apart. BrdU(1) cells were expressed as BrdU(1)
cells per mm2.
2.9. Tissue collection and immunoblotting
Animals were terminally anaesthetized with CO2 3 days after
BiTox IPLT injection or its vehicle, and fresh dorsal horn and
dorsal root ganglia (DRG) tissues collected. For protein extrac-
tion, each sample of dorsal horn or DRG was homogenized in
200 mL lysis buffer (1% Np-40, 20 mM Hepes pH7.4, 100 mM
NaCl, 100mMNaF, 1mMNa3VO4, 5mMEDTAwith 13 protease
inhibitor cocktail (SIGMA); 13 phosphatase inhibitor cocktail
(SIGMA)) and incubated on ice for 2 hours. Samples were then
centrifuged at 13,000 rpm for 15 minutes and supernatants
collected. Total protein concentration was assessed using
a bicinchoninic acid protein assay kit (Pierce Biotechnology, IL)
before each preparation of protein samples. Samples (10 mg of
proteins per well), 5 mL of cleaved SNAP25 (cSNAP25) and
uncleaved SNAP25 (uncSNAP25) controls (SIMA neuroblastoma
cells) were run on 10% Bis–Tris gels (Biorad Laboratories, CA) for
detection of cleaved SNAP25. Proteins were transferred onto
a PVDF membrane (Biorad). Membranes were blocked in 10 mM
Tris–HCl pH5 7.5, 150mMNaCl, 0.05% Tween 20 (SIGMA) and
0.24% I-Block (Tropix, MA) and incubated with anti-cSNAP25
primary antibody (1:1000) overnight at 4˚C. After washes, a goat
anti-rabbit horseradish peroxidase-conjugated secondary anti-
body was applied for 45minutes. Horseradish peroxidase activity
was visualized by applying PICO developer and using Chemi Doc
XRS (Biorad). Membranes were then washed and incubated with
glyceraldehyde 3-phosphate dehydrogenase antibody (1:1000,
Millipore Merck KGaA, Darmstadt, Germany; Cat, No.: MAB374)
for 45 minutes and further processed as described above. Signal
intensity was measured using Quantity One software (Biorad).
2.10. Statistical data analysis
Data analysis and statistical comparisons were performed by
SPSS (PASW) 18 (IBM) and GraphPad Prism, version 5 for
Windows, (GraphPad Software, San Diego, CA). All results are
presented as mean6SEM. Each group included 8 to 12 animals
in behavioral experiments or 6 animals in immunoblotting
approaches. Statistical analysis was performed by 2-way
analyses of variance with Bonferroni’s multiple comparison post
hoc tests for behavioral data. For immunoblotting, immunohis-
tochemistry results or when 2 groups were compared, Student’s
t-test was used. For all experiments, a value of P , 0.05 was
considered to be statistically significant.
3. Results
3.1. Motor effect of Bitox
No motor deficits were seen after injections of BiTox (200 ng) into
the plantar surface of the hindpaw.
3.2. Mechanical and thermal thresholds were not influenced
by intraplantar injection of BiTox in naive rats
Mechanical and thermal thresholds were monitored for 5 days
after IPLT injection of BiTox and were not different from vehicle
treated animals at these time points (Fig. 1).
Figure 1. Basal mechanical and thermal thresholds were not influenced by IPLT BiTox injection. Intraplantar (IPLT) injection of 200 ng BiTox had no effect on
mechanical thresholds (A) orwithdrawal latency to thermal stimulation (B). Themeasurementswere assessed for 5 days before injection to determine baseline pain
threshold (BL). Data are presented as means 6 SEM, P .0.05. n 5 4 animals per group.
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3.3. Effects of intraplantar injections of BiTox on
inflammatory and plantar incisional pain
3.3.1. BiTox does not reduce the efficacy of intraplantar
formalin and capsaicin injection
The response to acute injection with capsaicin or formalin was not
affected by BiTox pretreatment. Intraplantar injection with BiTox 3
days before 2% formalin injection did not reduce the number of
characteristic flinches in the early and late phases (Fig. 2A). The
increased thermal sensitivity seen after capsaicin injections (Fig.
2B) was also unchanged by IPLT BiTox injection given 3 days
before 0.3% capsaicin injection. C-Fos expression measured
2 hours after IPLT 0.3% capsaicin or 2% formalin injections was
also unchanged by IPLT BiTox injections in all laminae analyzed
(Fig. 2C and D).
3.3.2. Inflammatorymechanical but not thermal hyperalgesia
was acutely attenuated by intraplantar injections of BiTox
BiTox treatment injected into the ipsilateral hindpaw 24 hours
after IPLT CFA injection transiently reduced the hypersensitivity to
mechanical (between day 2 and day 3 post-BiTox, F(1,10)5 38.5,
P,0.001,Fig. 3A) but not thermal stimuli (Fig. 3B).Moreover,CFA-
induced paw swelling was reduced (0.675 6 0.026, t(14) 5 2.98,
Figure 3. Intraplantar BiTox transiently reduced CFA-induced mechanical but not thermal hypersensitivity. Intraplantar injection of BiTox given 24 hours after IPLT
injection of CFA transiently reduced mechanical (A) but not thermal hypersensitivity (B) on days 2 and 3 post-BiTox injection. Baseline pain threshold (BL) was
determined for 5 days before injection. Data are presented as means 6 SEM, *P . 0.05, **P , 0.01. n 5 6 to 8 animals per group.
Figure 2. Formalin and capsaicin responseswere not reduced by IPLT BiTox injection. (A) First and second phases of flinchesmeasured after 2% formalin injection
were unimpaired by IPLT BiTox injection into the ipsilateral hindpaw 3 days previously. (B) Thermal hyperalgesia that develops after 0.3% capsaicin injection is
unaffected by BiTox treatment 3 days previously. Total c-Fos counts in dorsal horn laminae I to V after 2% formalin (C) or 0.3% capsaicin injection (D) given 3 days
after BiTox injection into the ipsilateral hindpaw. No differences were seen between the number of c-Fos positive cells in the BiTox pretreated group and the vehicle
group (A). Data are presented as means 6 SEM, P . 0.05. n 5 6 animals per group.
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P 5 0.010) at 7 days compared with the ipsilateral control group
(0.762 6 0.012) after BiTox treatment.
3.3.3. Incisional sensitivity was acutely inhibited by
intraplantar injection of BiTox
Plantar incision increased response to mechanical stimulation
around the site of incision measured over 5 days. Twenty-four
hours after incision, rats received local BiTox injection or vehicle.
Intraplantar BiTox transiently reduced mechanical sensitivity from
1 to 2 days after treatment (between day 2 and day 3, F(1,14) 5
6.07, P , 0.027, Fig. 4).
3.4. Intraplantar BiTox injection reduced
plasma extravasation
Rats received a single IPLT injection of BiTox into the
ipsilateral paw and a single injection of vehicle into the plantar
surface of the contralateral paw. After 3 days the animals
received a tail vein injection of Evans blue (50 mg·kg21).
Fifteen minutes later 0.3% capsaicin was injected into the
ipsilateral (BiTox-treated) and contralateral (vehicle-treated)
paws to evoke plasma extravasation. After a further 15-minute
period the amount of dye extravasated or the extent of
extravasation was measured in paw skin tissue. In the vehicle-
injected paw, capsaicin injection induced a massive local
extravasation of blue dye. In contrast, intraplantar injection of
BiTox induced a reduction in dye extravasation compared
with the vehicle-treated paw (t(8)5 3.066, P5 0.015, Fig. 5B;
t(10) 5 3.011, P 5 0.013, Fig. 5C).
3.5. Reduced incorporation of BrdU after intraplantar
injection of BiTox
Incorporation of BrdU into proliferating keratinocytes was
measured at 4, 15, and 33 days (A, B, and C) after IPLT BiTox
injection. In the epidermis of rats pretreated with BiTox 14 and 32
days before systemic BrdU injection, the number of BrdU-labeled
cells was reduced compared with the contralateral paw (t(6) 5
2.472, P5 0.048 15 days; t(4)5 3.011, P5 0.040 33 days, Fig.
6C). In contrast, there was no significant difference between the
paw pretreated (3 days) with IPLT BiTox compared with the
contralateral paw (Fig. 6).
3.6. Intraplantar BiTox injection attenuated neuropathic pain
and secondary mechanical hyperalgesia
3.6.1. BiTox attenuated neuropathic pain
A single IPLT injection of BiTox 72 hours after SNI was sufficient
to reduce the mechanical hyperalgesia from 3 days up to
8 days, when the experiment was terminated (F(6.112) 5 5.178,
P5 0.0001, Fig. 7A). Moreover, BiTox blocks the development
of mechanical hyperalgesia when the toxin was injected 2
weeks before SNI (F(14,90) 5 7.215, P 5 0.0001, Fig. 7B).
However, IPLT BiTox did not reduce cold hypersensitivity
associated with the model and assessed using the acetone test
(Fig. 7C).
3.6.2. Secondary mechanical hyperalgesia in CFA model of
ankle joint inflammation is attenuated by intraplantar
injection of BiTox
BiTox was injected IPLT 3 days after intra-ankle joint injection of
CFA. Secondary mechanical hyperalgesia was measured on the
plantar surface of the hindpaw. There was a significant reduction
in mechanical hyperalgesia between the BiTox group and the
vehicle group (F(10,130) 5 3.271, P 5 0.0008, Fig. 8A) starting at
3 d after CFA treatment but no significant change in CFA-induced
edema in the ankle joint (Fig.8B).
Figure 5. Intraplantar BiTox inhibited capsaicin-induced extravasation. Rats were pretreated with IPLT BiTox (200 ng) or vehicle (contralateral paw) 3 days before
plasma extravasation was studied. Tail vein injection of Evans blue (50 mg·kg21) was given 15 minutes before bilateral IPLT injection of capsaicin. Tissue was
collected 15 minutes later. (A) The blue color of hindpaw skin was darker and more extensive in the contralateral vehicle paw compared with BiTox injected paw.
Histograms show dye concentration in formamide extract of ipsi- and contralateral paw tissue (B) and the area of Evans Blue extravasation generated from the
photographic record (C). Data are expressed as means 6 SEM, *P , 0.05. n 5 6 animals per group.
Figure 4. Plantar incision produced mechanical hypersensitivity that was
transiently reduced by IPLT BiTox injection. Effect of IPLT injection of BiTox
(200 ng) or vehicle on the mechanical withdrawal threshold measured with von
Frey filaments in a postsurgical pain model. Measurements were made before
injury to determine baseline pain threshold (BL) and 24 hours after the incision,
at which time BiTox was injected and behavior followed for 5 days. Mechanical
hypersensitivity was reduced on days 2 and 3 after BiTox injection. Data are
presented as means 6 SEM, *P , 0.05. n 5 8 animals per group.
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3.6.3. BiTox attenuated capsaicin-induced secondary
mechanical hyperalgesia
Capsaicin injection into the central plantar area of the hindpaw
induced thermal hypersensitivity close to the injection site and
secondary mechanical hyperalgesia in the zone that surrounds the
injection site (Fig. 9A). Secondary mechanical hyperalgesia is
thought to be maintained by A-nociceptor signaling amplified
centrally by sensitization of dorsal horn neurons (Treede et al., 2000,
Magerl et al., 2001). BiTox was delivered in the lateral plantar
surface 3 days before capsaicin injection in the central area of the
paw. Mechanical stimuli were applied to the area of secondary
hyperalgesia area on the lateral plantar surface. BiTox reduced the
hypersensitivity only in the area of secondary mechanical hyper-
algesia measured with Von Frey filaments (between 30 min and 1
hour, F(1,10) 5 27.2, P 5 0.001, Fig. 9B) or pin-prick (between 30
minutes and 2 hours, F(3,24)5 8.643,P5 0.0005,Fig. 9C). Thermal
hyperalgesia in the area of capsaicin injection and a marker of C-
fiber sensitization was not affected by BiTox treatment.
We also used capsaicin-induced secondary hyperalgesia to
examine the dose–response of BiTox, using 4 different doses (2,
50, 100, and 200 ng). BiTox was injected in the lateral plantar
surface 3 days before capsaicin injection in the central plantar
area. Mechanical stimuli were applied to the area of secondary
hyperalgesia on the lateral plantar surface. BiTox reduced the
hypersensitivity maximally at doses of 100 and 200 ng as
measured with Von Frey hairs (F(1,6) 5 119.503, P 5 0.001, Fig.
10A) or pinprick test (F(1,6) 5 51.0, P 5 0.001, Fig. 10B).
3.7. No evidence for transport of active BiTox in
peripheral neurons
We investigate whether BiTox was axonally transported to the
central nervous system. Dorsal horn andDRG tissuewere removed
3 days after IPLT injections of BiTox. Highly sensitive Western
blotting failed to demonstrate the presence of cleaved SNAP25 in
the dorsal horn andDRG ipsilaterally to the BiTox injection (Fig. 11A
and B). SiMa neuroblastoma cells cleaved with BiTox over 3 days
were used as a positive control for cSNAP25. The cSNAP25
control, but not uncleaved SNAP25 (uncSNAP25), was clearly
recognized by the cSNAP25 antibody. We also used the same
antibody directed against cSNAP25 to stain dorsal horn tissue
immunohistochemically. BiTox was injected IPLT and tissue for
immunohistochemistry collected at 3, 5, 7, and 32 days later. We
found no staining for cSNAP25 at any time point. As a positive
control we used spinal cord sections from rats injected intrathecally
with BiTox and survived 2 hours to 3 days without event. Extensive
positive staining was seen in these spinal cords (data not shown).
4. Discussion
BoNT/A has been shown to silence synaptic transmission
through specific proteolytic cleavage of the essential neuronal
Figure 7. Intraplantar BiTox attenuates SNI-induced mechanical hypersensitivity but not cold hypersensitivity. BiTox (200 ng) or vehicle were injected IPLT 3 days
after (A, C) SNI or 14 days before (B) SNI. Mechanical hyperalgesia was attenuated (A, B) but cold allodynia (C) was unaffected by treatment with BiTox injected 3
days after SNI. Baseline pain threshold (BL) was determined for 5 days before surgery or injection. Data are expressed asmeans6 SEM, **P, 0.01, ***P, 0.001
(A, B), P . 0.05 (C). n 5 9 to 10 animals per group.
Figure 6. Reduced incorporation of BrdU into keratinocytes after IPLT BiTox
treatment. Photomicrographs fromsections of cutaneous tissue (A) 14days after
vehicle or (B) BiTox IPLT pretreatment. There was a significant reduction of BrdU
positive keratinocytes 14days or 32daysbut not 3 days afterBiTox pretreatment
(C). Scalebar560mm.Arrowspoint toBrdU labeled cells in thebasal epidermis.
Data are presented as means6 SEM, *P, 0.05. n5 3 to 4 animals per group.
May 2016·Volume 157·Number 5 www.painjournalonline.com 1051
protein, SNAP25.31,42Botulinum neurotoxin/A-mediated syn-
aptic silencing is of long duration and high potency with
antinociceptive properties, but in clinical practice there
remains the possibility of muscle paralysis. Protein-stapling
technology allowed the re-assembly and safe production of
BoNT/A (BiTox), from 2 separate fragments.12 The resulting
protein was shown to retain synaptic silencing properties
between central neurons but failed to block transmission at the
neuromuscular junction probably due to steric problems
caused by the extensive remodeling of the molecule and its
inability to enter the neuromuscular junction. Indeed atomic
force microscopy has revealed that the synthetic molecule is
now “dumbbell” rather than globular in shape.12 Here we show
that a single IPLT injection of BiTox was nonparalysing but
effective in attenuating both A-nociceptor-mediated second-
ary mechanical hyperalgesia and neuropathic pain states
modeled in rats. However, BiTox did not reduce C-mediated
nociception but did inhibit plasma extravasation and inflam-
matory edema and reduced keratinocyte proliferation local to
the site of toxin injection.
4.1. Primary sensitization of C-fibers is not influenced by
intraplantar injection of BiTox
Previous preclinical studies using BoNT/A have yielded
conflicting results, particularly concerning effects on C-
nociceptors.30 This may have been in part because of various
factors, including dose and the use of different pain models
but in this study, we found that BiTox had no effect on the
thermal hyperalgesia that follows capsaicin treatment or
inflammation and thought to reflect the sensitization of C-
nociceptors20 or on the induction of c-Fos postsynaptically in
superficial dorsal horn neurons.24 Nevertheless previous
studies have shown an effect of BoNT/A using injection into
the forehead of human subjects, an area innervated by the
trigeminal nerve.16,17 Thus we cannot rule out the possibility
that primary afferents in different regions of the body respond
differentially to BoNT/A or BiTox. However, the mechanical
hypersensitivity that develops after surgical incision of the
hindpaw or CFA injection is mediated in part by A-
fibers4,9,24,34 and it may be that the transient loss of
mechanical (but not thermal) hypersensitivity reflects an
action on A-nociceptors. It is, however, unclear why the
effect should be transient and restricted to mechanical but not
thermal sensitivity. It has been shown that the intensity of
CFA-provoked inflammatory pain is dependent on proalgesic
mediators that are counterbalanced by endogenous analge-
sic mediators43,45 and it may well be that this balance is
transiently shifted towards analgesia when release of neuro-
peptides from nociceptors is blocked by BiTox.
4.2. BiTox reduces mechanical sensitivity associated with
neuropathic pain
A major conclusion from the present study was that BiTox
produced a profound long-term reduction in mechanical hyper-
algesia in a model of neuropathic pain. A single injection of BiTox
was effective in preventing both the development of hyperalgesia
and in attenuating the hyperalgesia once it had developed. The
analgesic effect of BiTox became significant 3 days after
application. Moreover, BiTox showed analgesic effects when it
was injected 2 weeks before SNI, preventing the appearance of
mechanical hyperalgesia for up to 11 days. A recent meta-
analysis of the clinical literature has also recommended local
BoNT/A treatment for peripheral neuropathic pain and only at
subparalytic doses.14
Figure 9. Intraplantar BiTox blocks capsaicin-induced secondary mechanical hyperalgesia. BiTox (200 ng) or vehicle were injected into the lateral plantar surface
of the rat hindpaw (A2). Three days later 0.3% capsaicin was injected into the central plantar area (A1) and mechanical secondary hyperalgesia was measured in
the lateral zone. Mechanical withdrawal threshold measured with von Frey filaments (B) or withdrawal response duration after pinprick stimulus (C), were
attenuated by BiTox pretreatment. The measurements were made before injection (BL) and then 30 minutes, 1 and 2 hours after capsaicin injection. Data are
expressed as means 6 SEM, *P , 0.05, ***P , 0.001. n 5 6 animals per group.
Figure 8.BiTox reduced secondary plantar mechanical hyperalgesia after CFA
injection into the ankle. BiTox (200 ng) or vehicle were injected IPLT 3 days after
CFA injection into the ankle joint. The mechanical withdrawal threshold was
measured with von Frey filaments before treatment as a basal pain threshold
(BL) and for 10 days. Intraplantar injection of BiTox attenuated plantar
mechanical hypersensitivity after CFA intra-ankle joint injection. Data are
presented as means6 SEM, *P, 0.05, **P, 0.01, ***P, 0.001. n5 6 to 8
animals per group.
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4.3. A-nociceptors as targets for BiTox
Increased mechanical sensitivity in peripheral neuropathic pain
states is thought to require central sensitization of dorsal horn
neurons. Central sensitization amplifies A-nociceptor inputs
signalling from tissue in and around the site of injury generating
secondary mechanical hyperalgesia that is thought to protect the
damaged tissue from further damage.28 We tested the hypoth-
esis that A-nociceptors signaling was specifically attenuated by
BiTox injections by examining the mechanical hyperalgesia that
develops around the site of injury in a number of rat models.26
Plantar mechanical hyperalgesia distance from the site of ankle
joint injection of CFA was reduced. We also generated secondary
hyperalgesia by injecting capsaicin into the plantar skin. BiTox,
delivered in the lateral plantar surface 3 days before capsaicin
injection in the central area of the paw, reduced the hypersen-
sitivity only in the surrounding area of mechanical hyperalgesia.
This implied that reducing the sensitivity of this subset of A-
nociceptors peripherally with a local injection of BiTox, diminished
the input to the dorsal horn.
Recent studies using human volunteers have also shown that
the area of secondarymechanical hyperalgesia produced by local
capsaicin injection was also significantly reduced by BoNT/A,
whereas intradermal administration of BoNT-A produced
a marked and specific decrease in noxious “pin-prick” mechan-
ical pain sensitivity: sensitivity to low-threshold mechanical and
thermal stimuli were largely unchanged.16,17,35 Thus in both
human and animal models the results strongly implied that local
injection of BoNT/A or BiTox attenuated mechanical hyperalgesia
through reduced A-nociceptor signaling.
4.4. Mechanism of action of BiTox
SNAP25 is the only definitely accepted molecular target of
BoNT/A action.30 Cleaving of SNAP25 by BoNT/A or BiTox
prevents the fusion of neurotransmitter-containing vesicles
with the presynaptic membrane and blocks transmitter re-
lease.42 Botulinum neurotoxin/A and BiTox are thought to
reduce plasma extravasation by inhibiting the release of
neuropeptides from subsets of C-nociceptors. The evidence
includes reports that have shown that the release of SP from rat
DRG cultures was inhibited by BoNT/A38,48 and that SNAP25
was cleaved by addition of BiTox to similar cultures.6 It was also
possible that inhibition of cytokine release from mast cells was
contributing to reduced extravasation. However, cytokine
release from mast cells uses SNAP23,21,37 which is insensitive
to BoNT/A.5 In humans, inhibition by BoNT/A was seen within
24 hours after toxin injection but the reduction of A-fiber
signaling takes much longer to develop. In rats, the full effect of
BiTox on A-nociceptor signaling is significant 3 days post-
injection, whereas in humans, loss of pin-prick mechanical
hyperalgesia can take up to 3 weeks to develop.35 Two
questions arise from these data: is BoNT/A or BiTox binding
Figure 11. Absence of cleaved SNAP25 in the dorsal horn and DRG after IPLT injection of BiTox. Rats received IPLT injection of BiTox (200 ng) 3 days before
sacrifice. The intensity of the bands for cSNAP25 antibody was normalized against the GADPH signal used as internal standard for protein loading in dorsal horn
(A). (A and B) show no evidence of cSNAP25 in the DRG or spinal cord 3 days after ipsilateral IPLT BiTox injection. Data are presented asmeans6 SEM. P. 0.05.
n 5 6 animals per group.
Figure 10. Effect of different doses of IPLT BiTox (2, 50, 100, 200 ng) on capsaicin-induced secondary hyperalgesia. Mechanical withdrawal thresholdsmeasured
with von Frey filaments (A) and withdrawal response duration (s) after pinprick stimulation (B). The measurements were assessed before injection and then 30
minutes, 1, and 2 hours after capsaicin injection. Data are expressed as means 6 SEM, *P , 0.05, **P , 0.01. n 5 4 to 6 animals per group.
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directly to A-nociceptors and does the delay in the attenuation
of mechanical hyperalgesia reflect transport of active botulinum
complex to the central terminals of primary afferents within the
dorsal horn where the release of neurotransmitter is inhibited by
the toxin?
There are some data to suggest that BoNT/A may act through
alternative pathways and bind directly to cutaneous A-
mechanoreceptors although the mechanisms are unclear.30,35
Nevertheless, if the only site of action of BiTox is on release of
neuropeptides from C-nociceptors, this raises the possibility that
C-fibers may be having a direct or more likely an indirect effect on
maintaining A-nociceptor function peripherally within cutaneous
tissues perhaps through trophic effects necessary to maintain
healthy tissue. Release of neuropeptides and other molecules
from C-fibers has been reported to have important effects on the
proliferation of keratinocytes in the epidermis.41 Neuropeptides,
particularly calcitonin gene-related peptide but not SP, released
from the C-fiber terminals were found to induce keratinocytes
proliferation and increase skin thickness and the close contact of
peptidergic nerve fibers with other cell types, including mast cells
and Langerhan cells, suggests a functional interaction. Previous
studies have also shown that peripheral nerve section in rats
results in a rapid reduction of keratinocyte proliferationmaximal at
3 days.22,23 Here we show that blocking release from C-fibers
reduced keratinocyte proliferation at 15 and 33 days after Bitox
treatment supporting the hypothesis that C-fibers actively
maintain the integrity of undamaged cutaneous tissues. Large
numbers of cytokines and chemokines have been identified in
skin tissue7 but it remains to be seen if any of these is involved in
maintaining A-fiber function. There is no doubt that this
population of A-nociceptors has a unique molecular profile,
expressing high levels of the activated kinase mTOR (the
mammalian target of rapamycin) and being capsaicin insensi-
tive.33,36 Indeed, local injections of mTOR inhibitor rapamycin into
the hindpaw will also attenuate the mechanical hypersensitivity
associated with peripheral neuropathy and secondary hyper-
algesia. It may well be that factors released by cutaneous tissues
act to maintain A-fibers through themTOR complex 1 pathway.33
A second explanation for the delay in the attenuation of
mechanical sensitivity after BiTox or BoNT/A injection is that this
represents the time taken for active toxin to be transported in
primary afferent fibers to the dorsal horn. Indeed there is some
evidence that trigeminal nerve fibers may transport BoNT/A.29,39
This would potentially result in the inhibition of neurotransmitter
release and block the induction of central sensitization. However,
although there is good evidence to suggest that active BoNT/A is
transported in central axons,1,40 evidence for transport of active
BoNT/A in peripheral nerves is controversial. In the present study,
we found no evidence that BiTox was transported centrally using
either Western blotting or immunohistochemistry.
5. Conclusions
In summary, we present evidence to show that local BiTox
injection has a strong antinociceptive effect predominantly on A-
nociceptors and suggest that the use of BiTox, a novel botulinum
conjugate, should be targeted specifically to pain conditions in
which A-nociceptors are thought to play a significant role.
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